Mesoblast Ltd Ads (MESO) 4.73 $MESO
Mesoblast Appoints Bill Burns, Former Chief Executive of Roche Pharmaceuticals, as Vice Chairman
GlobeNewswire - Thu Sep 01, 5:00AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Mr William (Bill) A. Burns, former Chief Executive Officer (CEO) of Roche Pharmaceuticals, has been appointed Vice Chairman of Mesoblast. In this role, Mr Burns will focus his considerable pharmaceutical industry expertise on activities relating to execution of major strategic partnerships and corporate transactions.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016
GlobeNewswire - Wed Aug 24, 5:41PM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today reported its consolidated financial results and operational highlights for the three months ended 30 June 2016 (fourth quarter of 2016) and year ended 30 June 2016 (FY16).
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast
GlobeNewswire - Fri Aug 19, 5:00AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the fourth quarter and full year ended June 30, 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Wednesday, August 24, 2016 and 9:00 am Australian Eastern Standard Time on Thursday, August 25 2016.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast's Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
GlobeNewswire - Mon Aug 01, 5:00AM CDT
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the 24-month results from the 100-patient, four-arm, randomized, placebo-controlled Phase 2 trial of its chronic low back pain (CLBP) product candidate MPC-06-ID were presented at the 24 Annual Scientific Meeting of the Spine Intervention Society (SIS) held in New Orleans July 27-30, and received the 2016 Best Basic Science Abstract award at the meeting.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.73 (+0.23), MPAA: 28.80 (+0.14), NAV: 21.97 (-0.48), RVNC: 17.56 (+0.52), WFC: 45.43 (-0.40), SYF: 27.37 (+0.31), MSB: 9.47 (+0.17)
Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update
GlobeNewswire - Mon May 09, 6:04PM CDT
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast
GlobeNewswire - Fri May 06, 7:53AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Monday, May 9 2016 and 9:00 am Australian Eastern Standard Time on Tuesday, May 10 2016.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.73 (+0.23), CBMG: 14.75 (+0.42), OCAT: 8.47 (+0.01), ZBH: 128.96 (+1.77), PFE: 34.13 (-0.15), LLY: 81.15 (+0.28), GSK: 43.60 (+0.39), GLPG: 69.35 (+1.76), AXSM: 7.75 (+0.02), OMER: 11.85 (+0.34), CANF: 2.72 (+0.10), AST: 4.69 (+0.18), AKTX: 8.69 (-0.26)
Investors' Radars Failed to Catch Mesoblast (MESO), Has Yours?
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 7:37AM CDT
Mesoblast is a stock flying under the radar as it looks well positioned for a solid gain given solid estimate revisions and an impressive Zacks Rank
MESO: 4.73 (+0.23)
Cell Therapy Industry: The Roads to Commercial Success
ACCESSWIRE - Wed Feb 03, 8:15AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 3, 2016 / A recent panel discussion at the Alliance for Regenerative Medicine State of the Industry Briefing (associated with Biotech Showcase 2016 in San Francisco) raised the issue of bio-manufacturing scale up for cell therapies as a great need for continued development (see webcast here: http://alliancerm.org/event/regenerative-medi...-briefing). Among representatives of large pharmaceutical companies, or biotech companies partnered for development with large pharmaceutical companies, there was a general consensus that scaling up manufacturing for production of cell therapeutics was still a work in progress, and after nearly a decade of investment, more expertise and new technologies were required prior to commercialization.
KOOL: 4.26 (+0.06), MESO: 4.73 (+0.23), PFE: 34.14 (-0.14), CLLS: 25.76 (+0.50), NVS: 81.92 (+0.40)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.64 (unch), GSK: 43.60 (+0.39), CLBS: 4.76 (+0.01), MESO: 4.73 (+0.23), ATHX: 1.98 (+0.01), BXLT: 46.02 (-0.18)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 4.73 (+0.23), AZN: 34.22 (+0.47), ATHX: 1.98 (+0.01), PRTO: 9.54 (+0.79), CELGZ: 1.20 (-0.05)
Low Back Pain - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/w4jxdk/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Low Back Pain Overview - Therapeutics Development - Pipeline Products for Low Back Pain - Overview - Pipeline Products for Low Back Pain - Comparative Analysis - Low Back Pain - Therapeutics under Development by Companies - Low Back Pain - Therapeutics under Investigation by Universities/Institutes - Low Back Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Low Back Pain - Products under Development by Companies - Low Back Pain - Products under Investigation by Universities/Institutes - Low Back Pain - Companies Involved in Therapeutics Development - Adynxx, Inc. - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immune Pharmaceuticals Inc. - Ipsen S.A. - MEDRx Co., Ltd. - Mesoblast Limited - Nektar Therapeutics - Orion Oyj - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - Stayble Therapeutics For more information visit http://www.researchandmarkets.com/research/w4..._back_pain
MESO: 4.73 (+0.23), PFE: 34.13 (-0.15), IMNP: 0.27 (unch), LLY: 81.15 (+0.28), PCRX: 37.62 (+0.81), NKTR: 19.49 (+0.34)
Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 4.73 (+0.23), PSTI: 1.64 (unch), CGEN: 6.79 (+0.09), CBLI: 1.64 (-0.03)
Chronic Heart Failure - Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4rlh37/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Heart Failure Overview - Therapeutics Development - Pipeline Products for Chronic Heart Failure - Overview - Pipeline Products for Chronic Heart Failure - Comparative Analysis - Chronic Heart Failure - Therapeutics under Development by Companies - Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes - Chronic Heart Failure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Heart Failure - Products under Development by Companies - Chronic Heart Failure - Products under Investigation by Universities/Institutes - Chronic Heart Failure - Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Caladrius Biosciences, Inc. - Capricor Therapeutics, Inc. - Celyad SA - Jiangsu Hengrui Medicine Co., Ltd. - Juventas Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mast Therapeutics, Inc. - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Vichem Chemie Research Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/4r...onic_heart
CAPR: 3.50 (-0.07), MESO: 4.73 (+0.23), MSTX: 0.13 (+0.01), PFE: 34.13 (-0.15), AMGN: 174.89 (+1.04), CLBS: 4.76 (+0.01), NVS: 81.92 (+0.40), CYAD: 22.58 (+2.46)
Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions
GlobeNewswire - Mon Jan 11, 7:00AM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure (CHF) of its proprietary cell-based medicine MPC-150-IM is planned to be substantially reduced. This follows communications last month between Mesoblast's development and commercial partner, Teva Pharmaceutical Industries Ltd., and the United States Food and Drug Administration (FDA).
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 07, 4:56PM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Research and Markets: Mesoblast Limited Product Pipeline Review 2015 - Analysis & Technologies
BusinessWire - Thu Dec 17, 11:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/dkjckd/mesoblast_limited) has announced the addition of the "Mesoblast Limited - Product Pipeline Review - 2015" company profile to their offering.
MESO: 4.73 (+0.23)
Mesoblast Limited Product Pipeline Review 2015 - Analysis & Technologies
M2 - Thu Dec 17, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb27zw/mesoblast_limited) has announced the addition of the "Mesoblast Limited - Product Pipeline Review - 2015" company profile to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of Mesoblast Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides brief overview of Mesoblast Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Mesoblast Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects Benefits of this Report: - Evaluate Mesoblast Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Mesoblast Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Mesoblast Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Mesoblast Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mesoblast Limited For more information visit http://www.researchandmarkets.com/research/lb...st_limited
MESO: 4.73 (+0.23)
Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
GlobeNewswire - Wed Dec 16, 3:57PM CST
Materially Strengthened Cash Reserves
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast Appoints Bill Burns, Former Chief Executive of Roche Pharmaceuticals, as Vice Chairman
GlobeNewswire - Thu Sep 01, 5:00AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced that Mr William (Bill) A. Burns, former Chief Executive Officer (CEO) of Roche Pharmaceuticals, has been appointed Vice Chairman of Mesoblast. In this role, Mr Burns will focus his considerable pharmaceutical industry expertise on activities relating to execution of major strategic partnerships and corporate transactions.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast Reports Financial Results and Operational Highlights for the Three Months and for the Year Ended 30 June 2016
GlobeNewswire - Wed Aug 24, 5:41PM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today reported its consolidated financial results and operational highlights for the three months ended 30 June 2016 (fourth quarter of 2016) and year ended 30 June 2016 (FY16).
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast to Host Fourth Quarter and Full Year Financial Results Conference Call and Webcast
GlobeNewswire - Fri Aug 19, 5:00AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the fourth quarter and full year ended June 30, 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Wednesday, August 24, 2016 and 9:00 am Australian Eastern Standard Time on Thursday, August 25 2016.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast's Full 24-Month Trial Results for Chronic Low Back Pain Presented at Spine Intervention Society Annual Meeting, Receive Award for Best Basic Science
GlobeNewswire - Mon Aug 01, 5:00AM CDT
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the 24-month results from the 100-patient, four-arm, randomized, placebo-controlled Phase 2 trial of its chronic low back pain (CLBP) product candidate MPC-06-ID were presented at the 24 Annual Scientific Meeting of the Spine Intervention Society (SIS) held in New Orleans July 27-30, and received the 2016 Best Basic Science Abstract award at the meeting.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Synchrony Financial, Wells Fargo and Navistar slip
AP - Tue Jun 14, 3:18PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily on Tuesday:
MESO: 4.73 (+0.23), MPAA: 28.80 (+0.14), NAV: 21.97 (-0.48), RVNC: 17.56 (+0.52), WFC: 45.43 (-0.40), SYF: 27.37 (+0.31), MSB: 9.47 (+0.17)
Mesoblast Reports Financial Results for Period Ended 31 March 2016 and Provides Corporate Update
GlobeNewswire - Mon May 09, 6:04PM CDT
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today reported its consolidated financial results and operational highlights for the third quarter and nine months ended 31 March 2016.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast to Host Third Quarter and Nine Months Financial Results Conference Call and Webcast
GlobeNewswire - Fri May 06, 7:53AM CDT
Mesoblast Limited (Nasdaq:MESO) (ASX:MSB) today announced it will report financial results for the third quarter/nine months ended March 31 2016 and provide a corporate update beginning at 7:00 pm Eastern Time on Monday, May 9 2016 and 9:00 am Australian Eastern Standard Time on Tuesday, May 10 2016.
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Osteoarthritis Pipeline Market H1 2016 Global Review Report
PR Newswire - Thu Apr 28, 1:00AM CDT
New market research titled "Osteoarthritis - Pipeline Review, H1 2016" is a report that provides an overview of the Osteoarthritis's therapeutic pipeline and helps strengthen R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
MESO: 4.73 (+0.23), CBMG: 14.75 (+0.42), OCAT: 8.47 (+0.01), ZBH: 128.96 (+1.77), PFE: 34.13 (-0.15), LLY: 81.15 (+0.28), GSK: 43.60 (+0.39), GLPG: 69.35 (+1.76), AXSM: 7.75 (+0.02), OMER: 11.85 (+0.34), CANF: 2.72 (+0.10), AST: 4.69 (+0.18), AKTX: 8.69 (-0.26)
Investors' Radars Failed to Catch Mesoblast (MESO), Has Yours?
Zacks Equity Research - Zacks Investment Research - Thu Apr 14, 7:37AM CDT
Mesoblast is a stock flying under the radar as it looks well positioned for a solid gain given solid estimate revisions and an impressive Zacks Rank
MESO: 4.73 (+0.23)
Cell Therapy Industry: The Roads to Commercial Success
ACCESSWIRE - Wed Feb 03, 8:15AM CST
REDONDO BEACH, CA / ACCESSWIRE / February 3, 2016 / A recent panel discussion at the Alliance for Regenerative Medicine State of the Industry Briefing (associated with Biotech Showcase 2016 in San Francisco) raised the issue of bio-manufacturing scale up for cell therapies as a great need for continued development (see webcast here: http://alliancerm.org/event/regenerative-medi...-briefing). Among representatives of large pharmaceutical companies, or biotech companies partnered for development with large pharmaceutical companies, there was a general consensus that scaling up manufacturing for production of cell therapeutics was still a work in progress, and after nearly a decade of investment, more expertise and new technologies were required prior to commercialization.
KOOL: 4.26 (+0.06), MESO: 4.73 (+0.23), PFE: 34.14 (-0.14), CLLS: 25.76 (+0.50), NVS: 81.92 (+0.40)
Global Ischemia Therapeutic Development Pipeline Review, H2 2015
M2 - Mon Feb 01, 8:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/4b8tfd/ischemia) has announced the addition of the "Ischemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Ischemia Overview - Therapeutics Development - Pipeline Products for Ischemia - Overview - Pipeline Products for Ischemia - Comparative Analysis - Ischemia - Therapeutics under Development by Companies - Ischemia - Therapeutics under Investigation by Universities/Institutes - Ischemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Ischemia - Products under Development by Companies - Ischemia - Products under Investigation by Universities/Institutes - Ischemia - Companies Involved in Therapeutics Development - Alize Pharma SAS - Amyndas Pharmaceuticals LLC - AnGes MG, Inc. - Apceth GmbH & Co. KG - Athersys, Inc. - Baxalta Incorporated - Caladrius Biosciences, Inc. - Cellmid Limited - CoDa Therapeutics, Inc. - CohBar, Inc. - Cynata Therapeutics Limited - DNAVEC Corporation - GlaxoSmithKline Plc - Hemostemix Ltd - IntelliCell BioSciences Inc. - Juventas Therapeutics, Inc. - Kasiak Research Private Limited - Lixte Biotechnology Holdings, Inc. - Mesoblast Limited - Miltenyi Biotec GmbH - Mirrx Therapeutics A/S - Multi Gene Vascular Systems Ltd - NoNO, Inc. - Nyken BV - Pathfinder Cell Therapy, Inc. - Pharmicell Co., Ltd. - Pluristem Therapeutics Inc. - Protagenic Therapeutics Inc. - ReNeuron Group Plc - Sihuan Pharmaceutical Holdings Group Ltd. - Stempeutics Research Private Limited - Targazyme, Inc. - Taxus Cardium Pharmaceuticals Group Inc. - TikoMed AB - U.S. Stem Cell, Inc. For more information visit http://www.researchandmarkets.com/research/4b8tfd/ischemia
PSTI: 1.64 (unch), GSK: 43.60 (+0.39), CLBS: 4.76 (+0.01), MESO: 4.73 (+0.23), ATHX: 1.98 (+0.01), BXLT: 46.02 (-0.18)
Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:16AM CST
Research and Markets (http://www.researchandmarkets.com/research/t6wjrw/peripheral) has announced the addition of the "Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) Overview - Therapeutics Development - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Overview - Pipeline Products for Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Comparative Analysis - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Therapeutics under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Development by Companies - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Products under Investigation by Universities/Institutes - Peripheral Arterial Disease (PAD)/ Peripheral Vascular Disease (PVD) - Companies Involved in Therapeutics Development - Alvogen Korea - AnGes MG, Inc. - AstraZeneca Plc - Athersys, Inc. - Bayer AG - Betagenon AB - Cardiolynx AG - CardioVascular BioTherapeutics, Inc. - Celgene Corporation - Diffusion Pharmaceuticals LLC - DNAVEC Corporation - Hemostemix Ltd - Mesoblast Limited - miRagen Therapeutics, Inc. - Multi Gene Vascular Systems Ltd - Nuo Therapeutics, Inc. - Proteon Therapeutics, Inc. - Recardio GmbH - Resverlogix Corp. - Sagene Pharmaceuticals, Inc. - Stemedica Cell Technologies, Inc. - Symic Biomedical, Inc. - Theravasc, Inc. - ViroMed Co., Ltd. - Yuyu Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/t6wjrw/peripheral
MESO: 4.73 (+0.23), AZN: 34.22 (+0.47), ATHX: 1.98 (+0.01), PRTO: 9.54 (+0.79), CELGZ: 1.20 (-0.05)
Low Back Pain - Pipeline Review, H2 2015
M2 - Wed Jan 20, 5:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/w4jxdk/low_back_pain) has announced the addition of the "Low Back Pain - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Low Back Pain, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Low Back Pain and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Low Back Pain Overview - Therapeutics Development - Pipeline Products for Low Back Pain - Overview - Pipeline Products for Low Back Pain - Comparative Analysis - Low Back Pain - Therapeutics under Development by Companies - Low Back Pain - Therapeutics under Investigation by Universities/Institutes - Low Back Pain - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Low Back Pain - Products under Development by Companies - Low Back Pain - Products under Investigation by Universities/Institutes - Low Back Pain - Companies Involved in Therapeutics Development - Adynxx, Inc. - Aestus Therapeutics, Inc. - Astellas Pharma Inc. - Eli Lilly and Company - Frontier Biotechnologies Co., Ltd - Grunenthal GmbH - Hisamitsu Pharmaceutical Co., Inc. - Immune Pharmaceuticals Inc. - Ipsen S.A. - MEDRx Co., Ltd. - Mesoblast Limited - Nektar Therapeutics - Orion Oyj - Pacira Pharmaceuticals, Inc. - Pfizer Inc. - Stayble Therapeutics For more information visit http://www.researchandmarkets.com/research/w4..._back_pain
MESO: 4.73 (+0.23), PFE: 34.13 (-0.15), IMNP: 0.27 (unch), LLY: 81.15 (+0.28), PCRX: 37.62 (+0.81), NKTR: 19.49 (+0.34)
Bone Marrow Transplantation Therapeutics Pipeline Report 2015
M2 - Wed Jan 20, 5:05AM CST
Research and Markets (http://www.researchandmarkets.com/research/4wppsb/bone_marrow) has announced the addition of the "Bone Marrow Transplantation - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bone Marrow Transplantation, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bone Marrow Transplantation and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bone Marrow Transplantation Overview - Therapeutics Development - Pipeline Products for Bone Marrow Transplantation - Overview - Pipeline Products for Bone Marrow Transplantation - Comparative Analysis - Bone Marrow Transplantation - Therapeutics under Development by Companies - Bone Marrow Transplantation - Therapeutics under Investigation by Universities/Institutes - Bone Marrow Transplantation - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bone Marrow Transplantation - Products under Development by Companies - Bone Marrow Transplantation - Products under Investigation by Universities/Institutes - Bone Marrow Transplantation - Companies Involved in Therapeutics Development - Anchor Therapeutics, Inc. - Boryung Pharmaceutical Co., Ltd. - Cleveland BioLabs, Inc. - Compugen Ltd. - Mesoblast Limited - Pluristem Therapeutics Inc. - Proteonomix, Inc. - Taiga Biotechnologies, Inc. - Targazyme, Inc. For more information visit http://www.researchandmarkets.com/research/4w...one_marrow
MESO: 4.73 (+0.23), PSTI: 1.64 (unch), CGEN: 6.79 (+0.09), CBLI: 1.64 (-0.03)
Chronic Heart Failure - Pipeline Review 2015
M2 - Thu Jan 14, 5:06AM CST
Research and Markets (http://www.researchandmarkets.com/research/4rlh37/chronic_heart) has announced the addition of the "Chronic Heart Failure - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Chronic Heart Failure, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Heart Failure and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Chronic Heart Failure Overview - Therapeutics Development - Pipeline Products for Chronic Heart Failure - Overview - Pipeline Products for Chronic Heart Failure - Comparative Analysis - Chronic Heart Failure - Therapeutics under Development by Companies - Chronic Heart Failure - Therapeutics under Investigation by Universities/Institutes - Chronic Heart Failure - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Chronic Heart Failure - Products under Development by Companies - Chronic Heart Failure - Products under Investigation by Universities/Institutes - Chronic Heart Failure - Companies Involved in Therapeutics Development - Amgen Inc. - AnGes MG, Inc. - ARCA biopharma, Inc. - Bayer AG - Bial - Portela & Ca, S.A. - Caladrius Biosciences, Inc. - Capricor Therapeutics, Inc. - Celyad SA - Jiangsu Hengrui Medicine Co., Ltd. - Juventas Therapeutics, Inc. - Laboratoires Pierre Fabre SA - Les Laboratoires Servier SAS - Mast Therapeutics, Inc. - Mesoblast Limited - Novartis AG - Pfizer Inc. - PhaseBio Pharmaceuticals, Inc. - Sanofi - Stemedica Cell Technologies, Inc. - Vichem Chemie Research Ltd. - Zensun (Shanghai) Sci & Tech Co., Ltd. For more information visit http://www.researchandmarkets.com/research/4r...onic_heart
CAPR: 3.50 (-0.07), MESO: 4.73 (+0.23), MSTX: 0.13 (+0.01), PFE: 34.13 (-0.15), AMGN: 174.89 (+1.04), CLBS: 4.76 (+0.01), NVS: 81.92 (+0.40), CYAD: 22.58 (+2.46)
Phase 3 Heart Failure Trial Size to be Substantially Reduced Following FDA Discussions
GlobeNewswire - Mon Jan 11, 7:00AM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that the size of the ongoing Phase 3 trial in chronic heart failure (CHF) of its proprietary cell-based medicine MPC-150-IM is planned to be substantially reduced. This follows communications last month between Mesoblast's development and commercial partner, Teva Pharmaceutical Industries Ltd., and the United States Food and Drug Administration (FDA).
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Mesoblast to Present at the 34th Annual J. P. Morgan Healthcare Conference
GlobeNewswire - Thu Jan 07, 4:56PM CST
Mesoblast Limited (ASX:MSB) (Nasdaq:MESO) today announced that it will present at the 34th Annual J. P. Morgan Healthcare Conference in San Francisco, CA, on Wednesday, January 13, 2016, at 3.30 p.m. PST/10.30am Thursday, January 14, 2016 (AEDT).
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
Research and Markets: Mesoblast Limited Product Pipeline Review 2015 - Analysis & Technologies
BusinessWire - Thu Dec 17, 11:42AM CST
Research and Markets (http://www.researchandmarkets.com/research/dkjckd/mesoblast_limited) has announced the addition of the "Mesoblast Limited - Product Pipeline Review - 2015" company profile to their offering.
MESO: 4.73 (+0.23)
Mesoblast Limited Product Pipeline Review 2015 - Analysis & Technologies
M2 - Thu Dec 17, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/lb27zw/mesoblast_limited) has announced the addition of the "Mesoblast Limited - Product Pipeline Review - 2015" company profile to their offering. This report provides comprehensive information on the current therapeutic developmental pipeline of Mesoblast Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - The report provides brief overview of Mesoblast Limited including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of Mesoblast Limited's human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects Benefits of this Report: - Evaluate Mesoblast Limited's strategic position with total access to detailed information on its product pipeline - Assess the growth potential of Mesoblast Limited in its therapy areas of focus - Identify new drug targets and therapeutic classes in the Mesoblast Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of Mesoblast Limited and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of Mesoblast Limited For more information visit http://www.researchandmarkets.com/research/lb...st_limited
MESO: 4.73 (+0.23)
Mesoblast Provides Strategic Update and Reports on First Quarter Financial Results
GlobeNewswire - Wed Dec 16, 3:57PM CST
Materially Strengthened Cash Reserves
MESO: 4.73 (+0.23), MSB: 9.47 (+0.17)
